However, the announcement from health officials says the new low prices for the federal insurance program will enable Medicare to cover Wegovy and Zepbound for patients with obesity and related comorbidities [co-occurring diseases] for the first time. Beneficiaries who will be eligible for lower-cost GLP-1 medications include individuals with a body mass index (BMI) of 27 or greater who have prediabetes or a history of cardiovascular disease
During an active shortage, the FDA exercises enforcement discretion that allows compounding pharmacies to produce the medication
And while the official guidance says they are all equivalent, the real-world experience of thousands of researchers tells a more nuanced story
Future studies are needed to confirm this association and highlight the underlying mechanism
For details, see the Chamomile tea section in our CL Answer about supplements for improving sleep
Looking ahead, the market is expected to continue growing as breakthroughs in novel molecular designs, oral formulations, and dual-target drugs push the boundaries of GLP-1 drug innovation